Compare · JNJ vs SYK
JNJ vs SYK
Side-by-side comparison of Johnson & Johnson (JNJ) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. JNJ focuses on Biotechnology: Pharmaceutical Preparations, while SYK focuses on Medical/Dental Instruments.
- JNJ is the larger of the two at $648.67B, about 6.2x SYK ($104.87B).
- Over the past year, JNJ is up 52.4% and SYK is down 26.7% - JNJ leads by 79.1 points.
- JNJ has been more active in the news (17 items in the past 4 weeks vs 7 for SYK).
- Both have 25 recent analyst ratings on file.
- Company
- Johnson & Johnson
- Stryker Corporation
- Price
- $270.79+0.59%
- $270.07-1.24%
- Market cap
- $648.67B
- $104.87B
- 1M return
- -0.89%
- -18.31%
- 1Y return
- +52.35%
- -26.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 17
- 7
- Recent ratings
- 25
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest JNJ
- Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
- Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
- New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
- DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
- CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
- Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director Hewson Marillyn A
Latest SYK
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)
- Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
- Director Brainerd Mary K bought $26,736 worth of shares (131 units at $204.09) (SEC Form 4)
- Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
- Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
- Stryker to participate in the 2026 Wells Fargo Healthcare Conference
- Group President Crotty Dylan Bram sold $144,915 worth of shares (441 units at $328.61) (SEC Form 4)
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)